North America Genetic Testing Market Size, Share & Trends Analysis Report By Technique (Polymerase chain reaction (PCR), Next Generation Sequencing, Cytogenetics, Microarrays, Others), By Application (Ancestry & Ethnicity, Traits Screening, Genetic Disease Carrier Status, New Baby Screening, Others), By Product (Consumables, Equipment, Software & Services), By End Use (Hospitals & Clinics, Diagnostic Laboratories, Others) and By Country (US, Canada) Forecasts, 2026-2034

North America Genetic Testing Market Size

The North America genetic testing market size was valued at USD 3.96 billion in 2025 and is projected to grow from USD 4.37 billion in 2026 to reach USD 9.65 billion by 2034, growing at a CAGR of 10.4% during the forecast period 2026-2034.

A genetic test is a type of medical testing that is carried out with the purpose of determining whether or not there have been any alterations to the chromosomal structure or the DNA sequence. Either the gene included within the DNA sequence can be directly recognised through the sequencing process or indirectly identified through a variety of methods of genetic testing. The use of genetic testing in the diagnosis of rare diseases and the practise of customised medicine is expanding at a rapid rate.

In addition, the growing number of technology improvements that have occurred over the course of the previous few years have made various prospects for market development available. The rapid expansion of the market is being aided by a number of factors, including an increase in the incidence of chronic illnesses and the creation of specialised testing kits for specialised treatment areas. According to the World Population Prospects 2020 Highlights published by the United Nations, there will be more than 1.5 billion people over the age of 65 years by the year 2050, which is an increase from 727 million in the year 2020. Because of the rising number of elderly people and their increased risk of developing chronic illnesses, there has been an uptick in the need for preventative diagnostics, in particular genetic testing.

The increased attention that governments of various countries are placing on regulating genetic testing and raising knowledge about them has effectively resulted in a speedier acceptance of these tests all around the world. Increased spending on research and development, along with large firms' already established footholds in the market, has made it difficult for new companies to break into the industry. Maintaining a competitive advantage in the market requires a number of critical characteristics to be satisfied, including innovation in product design, improvement in quality, and strong distribution relationships. For instance, in August 2020, Ricoh Company Ltd. and DNA Chip Research Inc. produced RICOH Standard DNA Series EGFR mutation Type001, which is a reference DNA plate to be utilised in the blood-based genetic testing in the diagnosis of lung cancer. This plate is intended to be used by many companies.

North America Genetic Testing Market Segmental Analysis

By Technique

The North America genetic testing market is segmented by technique into polymerase chain reaction (PCR), next generation sequencing, cytogenetics, microarrays, and others. Polymerase chain reaction (PCR) continues to be widely used for targeted genetic analysis across clinical diagnostics and laboratory applications. Next generation sequencing is gaining prominence because it enables broader genetic analysis and supports the identification of multiple variants within a single testing workflow. Cytogenetics remains important for evaluating chromosomal abnormalities, while microarrays support the simultaneous examination of numerous genetic markers. The others category includes additional molecular and genomic technologies applied across specialized diagnostic, research, and testing settings.

The adoption of genetic testing techniques across North America is supported by advanced laboratory infrastructure, strong investment in genomic research, and increasing integration of precision medicine into healthcare. Next generation sequencing is benefiting from expanding applications in inherited disease analysis, oncology, reproductive health, and personalized medicine, while PCR remains an established option for targeted testing. Improvements in automation, sequencing platforms, bioinformatics, and laboratory workflows are enhancing testing efficiency and analytical capabilities. However, testing costs, reimbursement policies, regulatory requirements, data interpretation, and the availability of skilled professionals can influence adoption across different healthcare settings.

Request Customizationto receive a tailored report.

By Application

The North America genetic testing market is categorized by application into ancestry & ethnicity, traits screening, genetic disease carrier status, new baby screening, and others. Ancestry and ethnicity testing is supported by consumer interest in genetic heritage, family history, and population backgrounds. Traits screening provides information related to inherited characteristics, while genetic disease carrier status testing is increasingly relevant for individuals seeking information about potential inherited conditions and reproductive risks. New baby screening represents an important clinical application because early identification of selected genetic and metabolic conditions can support timely evaluation and appropriate medical management. Growing awareness of genetic health is contributing to demand across both consumer and clinical applications.

The others category includes applications such as inherited disease assessment, genetic risk evaluation, reproductive testing, pharmacogenomics, and personalized healthcare. Growing availability of genetic testing services and increasing understanding of hereditary conditions are encouraging broader use across clinical and non-clinical settings. Healthcare providers are increasingly incorporating genetic information into disease assessment and treatment planning where appropriate. North America's advanced healthcare infrastructure, research capabilities, and biotechnology ecosystem support application expansion, although privacy concerns, ethical considerations, testing affordability, insurance coverage, and the complexity of interpreting genetic results continue to influence market adoption.

By Product

The North America genetic testing market is segmented by product into consumables, equipment, and software & services. Consumables include reagents, testing kits, cartridges, sample preparation materials, and other supplies required to perform genetic analyses. Increasing testing volumes across hospitals, diagnostic laboratories, research centers, and specialized testing facilities are supporting recurring demand for these products. Equipment includes PCR systems, sequencing platforms, microarray instruments, and other laboratory technologies used for genetic analysis. Continuous laboratory modernization and investments in advanced molecular diagnostic infrastructure are supporting the adoption of sophisticated genetic testing equipment across North America.

Software & services are becoming increasingly important as genetic testing generates substantial volumes of genomic data that require processing, interpretation, storage, and secure management. Bioinformatics platforms, data analysis software, laboratory information systems, genetic counseling, testing services, and interpretation solutions support the conversion of raw genetic information into useful clinical or research insights. The increasing adoption of next generation sequencing is further creating demand for advanced computational tools and data-management capabilities. Market development in this segment is influenced by data security requirements, interoperability, regulatory standards, technology investments, and the availability of specialized technical expertise.

By End Use

The North America genetic testing market is divided by end use into hospitals & clinics, diagnostic laboratories, and others. Hospitals and clinics represent significant end users as genetic testing becomes increasingly relevant to inherited disease diagnosis, reproductive health, prenatal assessment, oncology, and personalized medicine. Physicians can use genetic information to support selected diagnostic and treatment decisions, increasing the integration of testing into specialized clinical pathways. Diagnostic laboratories also represent a major end-use segment, providing genetic testing services for hospitals, physicians, researchers, and patients. The presence of advanced laboratory networks and specialized testing facilities is supporting increased testing capacity throughout the region.

The others category includes pharmaceutical companies, biotechnology firms, academic institutions, research organizations, and other facilities that use genetic testing for research and specialized applications. These end users apply genomic technologies to areas such as drug development, biomarker discovery, clinical research, population genomics, and targeted therapy development. North America's strong biotechnology and pharmaceutical ecosystem continues to support investment in advanced genomic technologies and testing platforms. However, market expansion across end-use settings is influenced by reimbursement structures, regulatory requirements, testing costs, data governance, laboratory infrastructure, and access to qualified genetic specialists and bioinformatics professionals.

Speak to an Analystto discuss market opportunities.

North America Genetic Testing Market Regional Analysis

The North American regional market has a considerable market share throughout the period covered by the projection and is anticipated to expand at a high compound annual growth rate (CAGR). Additionally, it is anticipated that the United States would produce additional money on the country level.

There were an estimated 16.9 million cancer survivors living in the United States as of January 2019, according to data provided by the National Cancer Institute. In addition, the number of people who have survived cancer is expected to rise up to 22.2 million by the year 2030. One of the key growth boosters for the North American market has been the increasing use of sophisticated cancer therapy choices. This trend has been compounded by the rising prevalence of cancer.

In addition, the Dana Farber Cancer Institute launched the Center for BRCA and Related Genes in August of 2020, with the intention of preventing BRCA-related malignancies through this introduction. Therefore, the increase in product approvals from the Food and Drug Administration (FDA) of the United States and the high concentration of significant players for the launch of breakthrough North America genetic testing market products are jointly driving the expansion of the market.

Furthermore, the initiatives taken by the federal government to raise awareness of diseases, favourable reimbursement policies, an increase in the demand for better patient care, technological advancements, a well-established medical infrastructure, and an increase in the number of people in their later years are definitively driving the growth of the market in the North America region.

List of Key and Emerging Players in North America Genetic Testing Market